The oncogenic ALK can be activated by ALK fusions in several cancers, such as NSCLC, anaplastic large cell lymphoma (ALCL), as well as by point mutations in neuroblastoma and anaplastic thyroid cancer [4, 5]. This evidence concerns the gene ALK and neuroblastoma.